Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced that Leukemia has published results from the Phase 2 trial known as PX-171-005 (NCT00721734) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE